Eagle's Eye View: Your Weekly CV Update From ACC.org

American College of Cardiology
  • 5.0 (1)
  • MEDICINE
  • UPDATED DAILY
Eagle's Eye View: Your Weekly CV Update From ACC.org

The weekly cardiovascular update from ACC.org Editor-in-Chief Kim Eagle, MD, MACC, covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.

  1. 6 DAYS AGO

    TAVR in Younger Patients; Atorvastatin vs. Rosuvastatin; Sedentary Behavior and Blood Pressure

    In this week’s View, Dr. Eagle looks at the outcomes of balloon-expandable transcatheter aortic valve replacement (TAVR) in younger patients. He then explores the comparative effectiveness and safety of atorvastatin versus rosuvastatin. Finally, Dr. Eagle discusses the results of the RESET-BP randomized trial that studied the effects of sedentary behavior’s reduction of blood pressure in desk workers.     Subscribe to Eagle’s Eye View

    7 min

  2. 6 DAYS AGO

    Top Four Trials from TCT 2024: EARLY TAVR, TRISCEND II for Tricuspid Regurgitation, ECLIPSE on orbital atherectomy, and CLEAR SYNERGY (OASIS 9) & colchicine treatment

    In this special edition of Eagle’s Eye View, Dr. Eagle looks four of the most important trials presented at the recent TCT Conference: 1) EARLY TAVR evaluating TAVR compared to clinical surveillance; 2) TRISCEND II looking at the Evoque transcatheter tricuspid valve replacement (TTVR) system for severe tricuspid regurgitation; 3) ECLIPSE evaluating orbital atherectomy prior to drug-eluting stent implant compared to conventional PCI; and 4) CLEAR SYNERGY (OASIS 9) assessing the effects of colchicine after PCI for a STEMI or large NSTEMI.  Subscribe to Eagle’s Eye View

    10 min

  3. 30 OCT

    Discontinuing Drug Treatment in HFrEF, Race and Sacubitril/Valsartan Use in HF, Systolic BP Polygenic Risk Score Treatment Responses

    In this week’s View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart failure and reduced ejection fraction (HFrEF). He then explores the effect of race and sacubitril/valsartan use in HF patients documented in a pooled analysis of the PARADIGM-HF and PARAGON-HF trials. Finally, Dr. Eagle discusses the utility of systolic blood pressure (BP) polygenic risk scores and the treatment response in people with hypertension.    Subscribe to Eagle’s Eye View

    9 min

  4. 23 OCT

    Anthracycline Cardiotoxicity in Cancer Patients; Arrhythmias, Autonomic Dysfunction and COVID-19; Lowering Non–HDL Cholesterol After MI

    In this week’s View, Dr. Eagle looks at anthracycline cardiotoxicity in treatment of cancer patients. He then explores a scientific statement from the American Heart Association on cardiac arrhythmias and autonomic dysfunction associated with COVID-19. Finally, Dr. Eagle discusses the SWEDEHEART registry and intensive early and sustained lowering of non–HDL cholesterol after MI and prognosis.    Subscribe to Eagle’s Eye View

    9 min

  5. 16 OCT

    Semaglutide and BP, HF Risk Assessment Using Biomarkers, DAPT After Drug-Eluting Stenting in ACS

    In this week’s View, Dr. Eagle looks at an individual patient data meta-analysis of semaglutide and blood pressure (BP). He then explores an analysis from COMBINE-AF on heart failure (HF) risk assessment using biomarkers in patients with atrial fibrillation. Finally, Dr. Eagle discusses short-term dual antiplatelet therapy (DAPT) after drug-eluting stenting in patients with acute coronary syndrome (ACS).  Subscribe to Eagle’s Eye View

    10 min

  6. 9 OCT

    CV Events After COVID Vaccine, Septal Reduction in Obstructive HCM, Acute Pulmonary Embolism Guideline Comparison

    In this week’s View, Dr. Eagle looks at cardiovascular events following COVID vaccination in adults. He then explores long-term outcomes after septal reduction therapies in obstructive hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses clinical practice guideline recommendations for acute pulmonary embolism.   Subscribe to Eagle’s Eye View

    11 min

  7. 2 OCT

    Hospital Survival After AAA Repair, Myocardial Fibrosis and Aortic Stenosis, MRA Use in HF

    In this week’s View, Dr. Eagle looks at sex-specific differences in alive hospital discharge following abdominal aortic aneurysm (AAA) repair. He then explores how diffuse interstitial fibrosis of the myocardium predicts outcomes in moderate and asymptomatic severe aortic stenosis. Finally, Dr. Eagle discusses the value of mineralocorticoid receptor antagonists (MRAs) in heart failure (HF).    Subscribe to Eagle’s Eye View

    8 min

  8. 25 SEPT

    Risk Stratification in Nonischemic Dilated Cardiomyopathy, 2024 Guideline for Perioperative CV Management for Noncardiac Surgery, Lipoprotein(a) and Cardiovascular Disease

    In this week’s View, Dr. Eagle looks at risk stratification in nonischemic dilated cardiomyopathy using CMR imaging. He then discusses the recent update of the Guideline for Perioperative CV Management for Noncardiac Surgery. Finally, Dr. Eagle talks about a review article on lipoprotein(a) and CVD.   Subscribe to Eagle’s Eye View

    9 min
See All (99)

About

The weekly cardiovascular update from ACC.org Editor-in-Chief Kim Eagle, MD, MACC, covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.

Information

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada